Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Opioid Use Disorder
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dundalk, Maryland

Conditions: Metastatic Prostate Cancer
Interventions: Naltrexone; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Age-Related Osteoporosis
Interventions: Teriparatide, Alendronate; Drug
Lead sponsor: Madhumathi Rao; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions: CTA018 Injection; Drug
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more

Conditions: Plantar Fasciitis
Interventions: DAXI 80 U, DAXI 120 U, Placebo; Biological · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more

Conditions: Alopecia Areata
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Northridge, California • Atlanta, Georgia • Gurnee, Illinois + 7 more

Conditions: Insomnia, Attention Deficit Hyperactivity Disorder
Interventions: eszopiclone, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 73
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 56 more

Conditions: Central Adrenal Insufficiency, Mifepristone
Interventions: Mifepristone; Drug
Lead sponsor: Tobias Else; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adverse Pregnancy Outcome
Interventions: Lovenox 40mg; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Acute Ischemic Stroke
Interventions: J147 Emulsion for Injection, Placebo; Drug · Other
Lead sponsor: Abrexa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Long Beach, California • Rockford, Illinois • Albany, New York + 2 more

Conditions: ALK-activated Tumors
Interventions: Ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Months to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Patritumab Deruxtecan; Drug
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Newnan, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NP001, Placebo; Drug
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more

Conditions: Streptococcus Pneumoniae
Interventions: Placebo, GEN-004 Low Dose, GEN-004 Low Dose + Adjuvant, GEN-004 Mid Dose, GEN-004 Mid Dose + Adjuvant, GEN-004 High Dose, GEN-004 High Dose + Adjuvant; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: HJB647 low dose, HJB647 high dose, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Bradenton, Florida • Inverness, Florida • Jacksonville, Florida + 2 more

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function; Drug · Device · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Malignant Melanoma
Interventions: Interleukin-2, Temozolomide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Influenza
Interventions: cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Idiopathic Scoliosis, Spondylolisthesis
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Julia Finkel; Other
Eligibility: 10 Years to 18 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions: ZYNRELEF 200Mg-6Mg Extended-Release Solution; Drug
Lead sponsor: Dr. Yannis Raftopoulos; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Holyoke, Massachusetts

Conditions: Gastroesophageal Reflux Disease
Interventions: Standard dose (once daily) PPI plus low-dose antidepressant, Double dose PPI plus evening placebo, Rabeprazole , placebo, placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
Interventions: Colchicine 0.5 MG Oral Tablet, Colchicine-Placebo; Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: New Haven, Connecticut • Gainesville, Florida • Tampa, Florida + 19 more

Conditions: CLN7
Interventions: AAV9/CLN7; Genetic
Lead sponsor: Benjamin Greenberg; Other
Eligibility: 1 Year to 18 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Low-dose Versus a High-dose Sublingual Buprenorphine Induction

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

Safety and Efficacy of J147 in Acute Ischemic Stroke

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

Study for the Treatment for CLN7 Disease